Tumor ablation techniques are advanced medical procedures designed to treat various types of tumors by destroying or damaging them using thermal energy, radiofrequency waves, microwaves, or extreme cold. These procedures offer minimally invasive alternatives to surgery, with benefits including reduced pain and quicker recovery times. Tumor ablation is applied in treating cancers of the liver, kidney, lung, and bone. Its precision, safety, and potential for outpatient treatment make it a vital tool in oncology for patients seeking effective and less invasive options.
Access full Reports @ https://www.databridgemarketresearch.com/pt/reports/switzerland-tumor-ablation-market
Data Bridge Market Research analyses that the Switzerland Tumor Ablation Market accounted for USD 96.65 million in 2022 and is expected to reach USD 269.95 million by 2030. The market is registering a CAGR of 13.70% during the forecast period of 2023 to 2030. The global rise in cancer cases and growing recognition of less invasive therapies have propelled the demand for tumor ablation procedures. As patients and medical professionals seek effective yet minimally disruptive treatments, the appeal of these procedures has increased, contributing to their growing adoption in the medical field.
Key Findings of the Study
Preference for minimally invasive procedures is expected to drive the market's growth rate
Minimally invasive treatments are favored by patients and doctors due to benefits like less pain, shorter hospital stays, and faster recovery. Tumor ablation procedures are particularly aligned with these preferences, as they offer effective cancer treatment without extensive surgery. This approach reduces physical trauma, enhances patient comfort, and enables a quicker return to daily activities, making tumor ablation an attractive choice for those seeking efficient and patient-friendly medical interventions.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Chemical Ablation, Thermal Ablation, and Others), Technology (Radiofrequency, Microwave, Cryoablation, Irreversible Electroporation (IRE), High Intensity Focused Ultrasound (HIFU), Laser, Fluoroscopy, Ultrasound, CT, MRI Imaging, and Others), Types of Treatment (Open Surgery, Laparoscopic and Percutaneous), Application (Liver, Kidney, Bone, Lung, Uterine Fibroid, Prostate, Breast, and Others), End User (Hospitals, Oncology Center and Others), Distribution Channel (Direct Sales and Third Party Distributors)
|
|
Market Players Covered
|
AngioDynamics (U.S.), Medtronic (Ireland), Boston Scientific Corporation (U.S.), BIOTRONIK SE & Co KG (Germany), EDAP TMS (France), HealthTronics, Inc. (U.S.), Misonix (U.S.), Medical Devices Business Services, Inc. (U.S.), Erbe Elektromedizin GmbH (Germany), MERMAID MEDICAL A/S (Denmark), BTG International Ltd (U.K.), BVM Medical Limited (U.K.), COMSOL INC. (Sweden), Cortex Technology (Denmark), CooperSurgical, Inc. (U.S.), AtriCure, Inc (U.S.), Abbott (U.S.), Integra LifeSciences (U.S.), Smith+Nephew (U.K.), CONMED Corporation (U.S.)
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework
|
Segment Analysis:
The Switzerland tumor ablation market is segmented on the basis of type, types of treatment, technology, application, end user, and distribution channel.
- On the basis of type, the market is segmented into chemical ablation, thermal ablation, and others. In 2023, the thermal ablation segment in Switzerland tumor ablation market is growing at the highest CAGR of 13.8% in the forecast period of 2023 to 2030 due to its effectiveness and versatility.
In 2023, the thermal ablation segment in Switzerland tumor ablation market is growing at the highest CAGR of 13.8% in the forecast period of 2023 to 2030
In 2023, the thermal ablation segment in Switzerland tumor ablation market is growing at the highest CAGR of 13.8% in the forecast period of 2023 to 2030 due to Utilizing heat-based methods like radiofrequency, microwave, and laser ablation, it targets tumors by raising temperatures to destroy cancer cells. This approach is minimally invasive, often outpatient, and results in reduced pain and shorter recovery times. The thermal ablation technique's broad applicability across various tumor types, coupled with its proven track record, positions it as a preferred choice among clinicians, thus driving its supremacy in the market.
- On the basis of types of treatment, the market is segmented into open surgery, laparoscopic and percutaneous. In 2023, percutaneous is expected to dominate the market with the CAGR of 13.9% in the forecast period of 2023 to 2030 due to its minimally invasive approach. Using thin needles, it targets tumors through the skin, reducing patient discomfort and enabling quicker recovery, thus driving its dominance.
- On the basis of technology, the market is segmented into radiofrequency, microwave, cryoablation, irreversible electroporation (IRE), high intensity focused ultrasound (HIFU), laser, fluoroscopy, ultrasound, CT, MRI imaging and others. In 2023, radiofrequency is expected to dominate the market with the CAGR of 15.9% in the forecast period of 2023 to 2030 as method employs high-frequency electrical currents to generate heat, destroying tumors. Its minimally invasive nature, widespread applicability, and proven outcomes contribute to its dominant position in the market.
In 2023, radiofrequency is expected to dominate the market with a CAGR of 15.9% in the forecast period of 2023 to 2030
In 2023, radiofrequency is expected to dominate the market with a CAGR of 15.9% in the forecast period of 2023 to 2030 as RF ablation utilizes high-frequency electrical currents to generate heat, effectively destroying tumors. Its minimally invasive approach, precise targeting, and versatility across various tumor types have propelled its adoption. As a reliable and established technique with favorable outcomes, RF ablation has emerged as the preferred choice for clinicians and patients, contributing to its supremacy in the market.
- On the basis of application, the market is segmented into liver, kidney, bone, lung, uterine fibroid, prostate, breast, and others. In 2023, the liver is expected to dominate the market with a 44.9% market with a CAGR of 13.4% in the forecast period of 2023 to 2030 due to the prevalence of liver tumors and the critical role the liver plays in the body's functions.
- On the basis of end user, the market is segmented into hospitals, oncology center and others. In 2023, hospitals are expected to dominate the market with a CAGR of 13.0% in the forecast period of 2023 to 2030 as ablation techniques like radiofrequency and microwave are effective for treating liver tumors, offering minimally invasive alternatives to surgery. As liver tumors pose significant health risks, their treatment holds paramount importance, contributing to the segment's prominence in the tumor ablation market.
- On the basis of distribution channel, the market is segmented into direct sales and third party distributors. In 2023, direct tender is expected to dominate the market with the CAGR of 13.6% in the forecast period of 2023 to 2030 as the procurement method involves directly inviting suppliers to submit bids for medical equipment and services.
Major Players
Data Bridge Market Research recognizes the following companies as the major Switzerland tumor ablation market players in Switzerland tumor ablation market are AngioDynamics (U.S.), Medtronic (Ireland), Boston Scientific Corporation (U.S.), BIOTRONIK SE & Co KG (Germany), EDAP TMS (France), HealthTronics, Inc. (U.S.), Misonix (U.S.), Medical Devices Business Services, Inc. (U.S.)
Market Developments
- In June 2022, IceCure Medical Ltd. has officially submitted a regulatory application to the Brazilian Health Regulatory Agency (ANVISA) seeking approval for ProSense. This cutting-edge cryoablation therapy employs liquid nitrogen to freeze and treat tumors, encompassing both benign and cancerous growths. The primary target areas for this innovative therapy are breast, kidney, bone, and lung cancers.
- In September 2021, privately held medical device company Francis Medical, Inc. has successfully concluded its Series B equity financing, securing USD 55 million. The company specializes in pioneering a distinctive and proprietary water vapor ablation therapy intended for addressing prostate, kidney, and bladder cancer.
For more detailed information about the tumor ablation market report, click here – https://www.databridgemarketresearch.com/pt/reports/switzerland-tumor-ablation-market
